These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 19850869

  • 41. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
    Seo BR, Min KJ, Cho IJ, Kim SC, Kwon TK.
    PLoS One; 2014; 9(4):e95588. PubMed ID: 24743574
    [Abstract] [Full Text] [Related]

  • 42. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J, Smith DL, Sang J, Friedland JC, He S, Sequeira M, Zhang C, Wada Y, Proia DA.
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [Abstract] [Full Text] [Related]

  • 43. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Dec; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 44. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.
    Exp Cell Res; 2014 May 01; 323(2):288-96. PubMed ID: 24631288
    [Abstract] [Full Text] [Related]

  • 45. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z, Zhang SL, Hu X, Tam KY.
    Eur J Pharmacol; 2018 Nov 05; 838():41-52. PubMed ID: 30213498
    [Abstract] [Full Text] [Related]

  • 46. Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
    Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci D, Marra E, Luberto L, D'Andrilli A, Coluccia P, Giovagnoli MR, Normanno N, Ruco L, Aurisicchio L, Mancini R, Ciliberto G.
    Oncotarget; 2013 Aug 05; 4(8):1253-65. PubMed ID: 23896512
    [Abstract] [Full Text] [Related]

  • 47. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.
    Ann Oncol; 2013 Aug 05; 24(8):2080-7. PubMed ID: 23559152
    [Abstract] [Full Text] [Related]

  • 48. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
    Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, Sorger PK, Jacks T, Neel BG, Lauffenburger DA.
    Cancer Res; 2010 May 01; 70(9):3843-50. PubMed ID: 20406974
    [Abstract] [Full Text] [Related]

  • 49. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 May 01; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 50. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
    Qu GP, Shi M, Wang D, Wu JH, Wang P, Gong ML, Zhang ZJ.
    BMC Pulm Med; 2021 Jul 01; 21(1):208. PubMed ID: 34210314
    [Abstract] [Full Text] [Related]

  • 51. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
    Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.
    Mol Cancer Ther; 2008 Apr 01; 7(4):874-9. PubMed ID: 18413800
    [Abstract] [Full Text] [Related]

  • 52. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
    Mol Cancer Ther; 2010 Jun 01; 9(6):1647-56. PubMed ID: 20530710
    [Abstract] [Full Text] [Related]

  • 53. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
    Song JY, Kim CS, Lee JH, Jang SJ, Lee SW, Hwang JJ, Lim C, Lee G, Seo J, Cho SY, Choi J.
    Invest New Drugs; 2013 Dec 01; 31(6):1458-65. PubMed ID: 24068620
    [Abstract] [Full Text] [Related]

  • 54. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 01; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
    Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B.
    Blood; 2010 Jun 03; 115(22):4455-63. PubMed ID: 20299510
    [Abstract] [Full Text] [Related]

  • 57. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
    Kim Y, Ko J, Cui Z, Abolhoda A, Ahn JS, Ou SH, Ahn MJ, Park K.
    Mol Cancer Ther; 2012 Mar 03; 11(3):784-91. PubMed ID: 22228822
    [Abstract] [Full Text] [Related]

  • 58. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH, Xue A, Baxter RC, Pavlakis N, Smith RC.
    Neoplasia; 2016 Jul 03; 18(7):425-35. PubMed ID: 27435925
    [Abstract] [Full Text] [Related]

  • 59. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R.
    Oncotarget; 2015 Sep 22; 6(28):26090-103. PubMed ID: 26325669
    [Abstract] [Full Text] [Related]

  • 60. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
    Pan H, Jiang T, Cheng N, Wang Q, Ren S, Li X, Zhao C, Zhang L, Cai W, Zhou C.
    Oncotarget; 2016 Aug 02; 7(31):49948-49960. PubMed ID: 27409677
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.